Acredit’s Anne Hansen Ree has penned a new article looking into the use of precision medicine in cancer. In it, Anne gives us a brief history of the use of precision medicine, such as the so-called “Next Generation Sequencing” (NGS for short) in the diagnosis and treatment of various cancers. The article gives us a good outline of both the benefits and drawbacks of conclusions drawn based on studies using genetic profiling using the MetActions project’s results as an example. Anne’s article is a good introduction to the use of genetics in cancer research, and is a must-read for anyone interested in why we often hear about fascinating results that then go on to work in only a handful of patients.
- EV Phenotype Impact and Function of Monocytes in CRC
- New Marker for Risk of Liver Metastasis from Rectal Cancer Identified